Oxford BioMedica halts trial due to poor recruitment

Oxford BioMedica, a gene-based biopharmaceutical company, has made a strategic decision to close the US trial of its TroVax product on patients with progressive hormone refractory prostate cancer (HRPC) because recruitment has been much slower than originally anticipated.

Oxford BioMedica, a gene-based biopharmaceutical company, has made a strategic decision to close the US trial of its TroVax product on patients with progressive hormone refractory prostate cancer (HRPC) because recruitment has been much slower than originally anticipated.

This is largely because competition for suitable patients with HRPC has been high following a change in the prostate cancer treatment landscape in the US, with new products available and other clinical trials targeting the same indication.

The firm said that whilst early data from the study are encouraging, the board has decided to focus on investigator-led Phase II studies, currently in the UK.

The data that had been collected indicated a trend towards increased time to disease progression in patients who received TroVax plus chemotherapy drug docetaxel versus those who received docetaxel alone.

The company said these data "validate the observation that Oxford BioMedica's pre-treatment biomarker can identify patients most likely to benefit from treatment with TroVax".

Looking ahead, the company expects two further investigator-led Phase II studies of TroVax in mesothelioma and ovarian cancer to be initiated in the UK by academic collaborators in the fourth quarter of 2012.

John Dawson, Chief Executive Officer of Oxford BioMedica, said: "Whilst changes to the treatment landscape in the US have challenged recruitment into our prostate cancer trial, early data support the use of our biomarker which is an important step in the ongoing clinical development of TroVax. We are focused on our Phase II programme with academic collaborators in the UK which will further support the potential for TroVax in the treatment of multiple cancer indications."

The share price fell 5.45% to 2.60p by late morning.

NR

Recommended

The ten highest dividend yields in the FTSE 100
Income investing

The ten highest dividend yields in the FTSE 100

Rupert Hargreaves takes a look at the companies with the highest dividend yields in the UK’s blue-chip index
6 Feb 2023
The outlook for Shell shares is mixed, despite bumper profits
Energy stocks

The outlook for Shell shares is mixed, despite bumper profits

With profits surging, it looks as if Shell is on a roll, but the company’s growth from here is hard to see as Rupert Hargreaves explains.
6 Feb 2023
The top funds to invest in
Funds

The top funds to invest in

As market volatility and recessionary fears continue, here are the most popular funds, stocks and trusts investors are putting their money into accord…
2 Feb 2023
The top ten dividend stocks in the FTSE 250
Share tips

The top ten dividend stocks in the FTSE 250

The average FTSE 250 dividend yield is around 4%, but many stocks yield much more. Rupert Hargreaves picks the best FTSE 250 stocks for income investo…
17 Jan 2023

Most Popular

Share tips of the week – 3 February 2023
Investments

Share tips of the week – 3 February 2023

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages
3 Feb 2023
The best one-year fixed savings accounts - February 2023
Savings

The best one-year fixed savings accounts - February 2023

Earn almost 5% on one-year fixed savings accounts.
6 Feb 2023
Will energy prices go down in 2023?
Personal finance

Will energy prices go down in 2023?

Wholesale gas prices are on a downward trajectory, but does this mean lower energy bills later this year?
6 Feb 2023